Boehringer Ingelheim Vietnam announced the launch of its poultry vaccine VAXXITEK® HVT+IBD+ND at the first VAXXITEK symposium in Hà Nội on April 12.

The VAXXITEK symposium - XXI Century Technology Vaccine is a yearly event with the purpose of updating on the latest news on poultry disease, production management and innovative technological applications.

Vaccine technology focuses on safety and efficacy balance. This requires excellent protection against diseases and is safe for animals and the environment that supports all present poultry breeds and diverse management conditions.

This innovative product - VAXXITEK® HVT+IBD+ND is effective for the vaccination of healthy 18 to 19-day-old chicken embryos as well as one-day-old chickens against classic and variant infectious bursal disease (IBD), Newcastle disease (ND) and Marek’s disease (MD).

VAXXITEK® HVT+IBD+ND represents a breakthrough in hatchery vaccination. As the first and only three-in-one vaccine in the Việt Nam‘s market, it provides a strong immune foundation and optimised protection against IBD, ND and MD.

VAXXITEK® HVT+IBD+ND provides producers a simplified vaccination protocol that is flexible and with protection against three of the most infectious and commercially disruptive poultry diseases.

Dr. Torsten Hardge, Head of Animal Health at Boehringer Ingelheim Animal Health Vietnam, said: “We are confident this vaccine will improve flock health, and production performance while simplifying the vaccination process, as expected by our customers from the VAXXITEK® brand.”

Boehringer Ingelheim will manufacture VAXXITEK® HVT+IBD+ND from its site in Gainesville, Georgia, USA which produces more than 60 billion doses of poultry vaccine a year for use in the United States and over 60 other countries. — VNS